Comparative Pharmacology
Head-to-head clinical analysis: ADLYXIN versus MOUNJARO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLYXIN versus MOUNJARO.
ADLYXIN vs MOUNJARO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates GIP and GLP-1 receptors, potentiating glucose-dependent insulin secretion from pancreatic beta cells, reducing glucagon secretion, slowing gastric emptying, and promoting satiety via hypothalamic appetite regulation.
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
Subcutaneous injection once weekly. Starting dose: 2.5 mg for 4 weeks, then increase to 5 mg for at least 4 weeks. For additional glycemic control, may increase in 2.5 mg increments after at least 4 weeks on current dose. Maximum dose: 15 mg once weekly.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Achieves steady-state after 4-5 weeks.
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Primarily eliminated via proteolytic degradation, with the parent drug not significantly excreted renally or in feces. Small amounts of metabolites may be excreted in urine and feces.
Category C
Category C
GLP-1 Receptor Agonist
Dual GIP/GLP-1 Receptor Agonist